Evidence map›Paper›PMID 26527522›Full record

ArticleHuman pathology2016

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Ashley Cimino-Mathews, Elizabeth Thompson, Janis M Taube, Xiaobu Ye, Yao Lu, Alan Meeker, Haiying Xu, Rajni Sharma, Kristen Lecksell, Toby C Cornish and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 2 syntheses or guidelines pooled it, 336 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ashley Cimino-MathewsDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287; Department of Oncology, The Johns Hopkins Hospital, Baltimore, MD 21287. Electronic address: acimino@jhmi.edu.
Elizabeth ThompsonDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Janis M TaubeDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287; Department of Dermatology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Xiaobu YeDepartment of Neurosurgery, The Johns Hopkins Hospital, Baltimore, MD 21287.
Yao LuDepartment of Oncology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Alan MeekerDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Haiying XuDepartment of Dermatology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Rajni SharmaDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Kristen LecksellDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Toby C CornishDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Nathan CukaDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Pedram ArganiDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287; Department of Oncology, The Johns Hopkins Hospital, Baltimore, MD 21287.
Leisha A EmensDepartment of Oncology, The Johns Hopkins Hospital, Baltimore, MD 21287. Electronic address: emensle@jhmi.edu.
Johns Hopkins Hospital · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1(+) TILs, but only 21% had PD-L1(+) carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P = .04). Eighty-nine percent of PD-L1(+) carcinomas contained brisk TIL infiltrates, compared to only 24% of PD-L1(-) carcinomas; this included CD3(+) (P = .02), CD4(+) (P = .04), CD8(+) (P = .002), and FoxP3(+) T cells (P = .02). PD-L1(+) PBCs were more likely to contain PD-L1(+) TIL than PD-L1(-) PBCs (P = .04). Peripheral lymphoid aggregates were present in 100% of PD-L1(+) compared to 41% of PD-L1(-) PBC (P < .001). No patient with PD-L1(+) PBC developed distant recurrence, compared to 15% of patients with PD-L1(-) PBC. For the matched PBC and MBC cohort, 2 patients (8%) had PD-L1(+) tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.

Indexed as

Tumor MicroenvironmentAdultAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorBreast NeoplasmsCarcinomaFemaleHumansImmunohistochemistryLymphocyte CountLymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm GradingNeoplasm InvasivenessB7-H1 AntigenBiomarkers, TumorCD274 protein, humanMetastatic breast cancerPD-L1Primary breast cancerTumor infiltrating lymphocytesTumor microenvironment

Identifiers

PMID26527522
PMCPMC4778421
OpenAlexW1896351481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.